2025 IVD Volume-Based Procurement Outlook: Centralized Procurement Deepens as the Industry Accelerates Change

Volume-based procurement of IVD reagents continues to advance in 2025: Anhui leads centralized procurement of cardiac marker reagents, Gansu leads procurement of routine laboratory reagents, and Jiangsu includes genetic testing services in centralized procurement for the first time.

Xinke Vision

Published January 22, 2025

In 2025, volume-based procurement of in vitro diagnostics (IVD) reagents continues to deepen on the basis of the multi-province alliance procurements of 2023 and 2024, with far-reaching implications for IVD manufacturers' product pricing and the market landscape.

Key Procurement Directions

According to publicly available information, centralized procurement in 2025 mainly revolves around the following areas:

Anhui-led volume-based procurement of cardiac marker reagents: After the 25-province alliance procurement of IVD reagents in 2023 and the 28-province volume-based procurement of tumor marker and thyroid function test reagents in 2024, the Anhui Healthcare Security Administration is pressing ahead with centralized procurement across its immunoassay product lines, and the cardiac marker panel is expected to expand further.

Gansu-led volume-based procurement of routine blood, stool, and urine reagents and test strips: Routine laboratory products, which are in high demand at medical institutions and are already highly localized, have entered the scope of volume-based procurement for the first time.

Jiangsu procurement of oncology genetic testing services: The award results of the volume-based procurement of non-invasive prenatal genetic testing services conducted in 2024 take effect on January 1, 2025 — the first time testing services have been included in centralized procurement.

Impact on the Industry

At the national level, provinces in central and eastern China are in principle required to carry out centralized volume-based procurement of at least one product each, and in 2025 the number of national and provincial alliance procurement items across the country is expected to exceed 700.

Under the twin pressures of volume-based procurement and medical insurance price governance, the IVD industry is undergoing rapid structural change. On one hand, product prices are falling and manufacturers' margins are being squeezed; on the other, centralized procurement helps winning bidders expand their market share by trading price for volume, and industry concentration is expected to rise further. For reagent manufacturers, the breadth of their product portfolios, cost-control capability, and distribution strength have become decisive for staying competitive in a centralized-procurement environment.